Biogen Inc. $BIIB Stock Bought by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC grew its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.7% during the third quarter, Holdings Channel.com reports. The firm owned 10,585 shares of the biotechnology company’s stock after acquiring an additional 2,896 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Biogen were worth $2,391,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in Biogen in the 2nd quarter valued at $3,453,878,000. Primecap Management Co. CA bought a new stake in Biogen during the 2nd quarter worth about $3,274,304,000. Wellington Management Group LLP lifted its position in Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after buying an additional 155,828 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Biogen by 10,085.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company’s stock worth $557,042,000 after buying an additional 2,441,884 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Biogen by 1,524.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after buying an additional 2,041,161 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB opened at $249.59 on Friday. The firm has a 50-day moving average of $236.83 and a 200-day moving average of $206.86. Biogen Inc. has a one year low of $160.36 and a one year high of $261.00. The company has a market cap of $36.89 billion, a PE ratio of 106.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same period in the prior year, the firm earned $4.81 EPS. Biogen’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities analysts forecast that Biogen Inc. will post 12.46 earnings per share for the current year.

Key Stories Impacting Biogen

These are some of the BIIB stories that stood out recently:

  • Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
  • Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
  • Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article

Analysts Set New Price Targets

BIIB has been the subject of several analyst reports. Wolfe Research upgraded Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a report on Thursday, August 13th. Robert W. Baird upped their target price on Biogen from $250.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. HSBC increased their price target on Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. UBS Group raised their price target on Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, Zacks Research raised Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $255.45.

Get Our Latest Research Report on BIIB

Biogen Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Read More

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.